MADDEN SECURITIES Corp Purchases New Stake in Becton, Dickinson and Company (NYSE:BDX)

MADDEN SECURITIES Corp bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 1,795 shares of the medical instruments supplier’s stock, valued at approximately $407,000.

A number of other institutional investors and hedge funds also recently modified their holdings of BDX. Arlington Trust Co LLC grew its position in shares of Becton, Dickinson and Company by 163.3% during the 4th quarter. Arlington Trust Co LLC now owns 495 shares of the medical instruments supplier’s stock valued at $112,000 after buying an additional 307 shares during the last quarter. Equitable Trust Co. lifted its holdings in Becton, Dickinson and Company by 15.7% in the fourth quarter. Equitable Trust Co. now owns 8,322 shares of the medical instruments supplier’s stock worth $1,888,000 after acquiring an additional 1,132 shares during the last quarter. Quilter Plc acquired a new position in Becton, Dickinson and Company in the fourth quarter valued at approximately $227,000. Ferguson Wellman Capital Management Inc. grew its holdings in shares of Becton, Dickinson and Company by 8.8% during the fourth quarter. Ferguson Wellman Capital Management Inc. now owns 2,353 shares of the medical instruments supplier’s stock valued at $534,000 after purchasing an additional 190 shares during the last quarter. Finally, Savant Capital LLC raised its position in shares of Becton, Dickinson and Company by 85.9% during the 4th quarter. Savant Capital LLC now owns 14,628 shares of the medical instruments supplier’s stock worth $3,319,000 after purchasing an additional 6,759 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 0.2 %

NYSE:BDX opened at $229.35 on Tuesday. The stock has a market cap of $66.51 billion, a price-to-earnings ratio of 38.10, a PEG ratio of 1.65 and a beta of 0.40. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.13. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $251.99. The business has a fifty day moving average of $232.07 and a 200-day moving average of $234.02.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Equities analysts predict that Becton, Dickinson and Company will post 14.41 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be given a $1.04 dividend. The ex-dividend date is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.81%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 69.10%.

Becton, Dickinson and Company announced that its Board of Directors has authorized a share buyback program on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to purchase shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on BDX shares. Piper Sandler upped their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 28th. StockNews.com lowered shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and an average price target of $283.00.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 4,483 shares of the company’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $221.01, for a total value of $990,787.83. Following the completion of the sale, the executive vice president now owns 24,345 shares in the company, valued at $5,380,488.45. This represents a 15.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Jeffrey William Henderson bought 1,500 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were purchased at an average cost of $233.62 per share, for a total transaction of $350,430.00. Following the completion of the acquisition, the director now owns 8,015 shares of the company’s stock, valued at $1,872,464.30. This trade represents a 23.02 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 9,844 shares of company stock valued at $2,210,716. 0.36% of the stock is owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.